Monte Rosa Therapeutics (GLUE) Interest Coverage Ratio (2020 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly Interest Coverage Ratio came in at 0.41 in Q1 2026, down 106.82% year-on-year from 5.98 in Q1 2025, and up 5.43% quarter-over-quarter from 0.43 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Interest Coverage Ratio history runs 7 years deep, the most recent figure standing at 0.41 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio fell 106.82% year-over-year to 0.41 in Q1 2026; TTM through Mar 2026 was 1.21, a 317.97% decrease from a year earlier, with the FY2025 full-year figure at 0.47, up 58.16% from the prior year.
- Interest Coverage Ratio grew to 0.41 in Q1 2026 per GLUE's latest filing, from 0.43 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 5.98 in Q1 2025 and bottomed at 2.08 in Q3 2025.
- The 5-year median for Interest Coverage Ratio is 0.52 (2024), against an average of 0.27.
- Across the five-year window, Interest Coverage Ratio slumped 331.35% in 2022 and soared 1250.83% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.98 in 2022, then jumped by 34.82% to 0.64 in 2023, then soared by 277.91% to 1.14 in 2024, then sank by 137.88% to 0.43 in 2025, then rose by 5.43% to 0.41 in 2026.
- Per Business Quant, the three latest GLUE Interest Coverage Ratio figures stand at 0.41 (Q1 2026), 0.43 (Q4 2025), and 2.08 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -0.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.41 |
| Dec 31, 2025 | -0.43 |
| Sep 30, 2025 | -2.08 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | 5.98 |
| Dec 31, 2024 | 1.14 |
| Sep 30, 2024 | -1.33 |
| Jun 30, 2024 | -1.56 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -0.64 |
| Sep 30, 2023 | -0.52 |
| Jun 30, 2023 | -0.51 |
| Mar 31, 2023 | -0.47 |
| Dec 31, 2022 | -0.98 |
| Sep 30, 2022 | -0.39 |
| Jun 30, 2022 | -0.92 |
| Mar 31, 2022 | -0.60 |
| Dec 31, 2021 | -1.32 |
| Sep 30, 2021 | -0.24 |
| Jun 30, 2021 | -0.21 |